The present invention relates to the field of catalysts, and provides a porous layered transition metal dichalcogenide (TMD) and a preparation method and use thereof. The preparation method includes the following steps: (1) mixing silica microspheres, a transition metal salt and an elemental chalcogen, and pressing to obtain a tablet, the silica microspheres having a same or different particle diameters; and (2) sintering the tablet under hydrogen, and removing the silica microspheres to obtain the porous layered TMD. The porous layered TMD prepared by the method of the present invention has a high lattice edge exposure, which provides more active sites and higher catalytic activity, so the porous layered TMD can effectively catalyze the oxidation of alcohols to aldehydes or sulfides to sulfoxides under visible light irradiation.

The present invention relates to the field of catalysts, and provides a porous layered transition metal dichalcogenide (TMD) and a preparation method and use thereof. The preparation method includes the following steps: (1) mixing silica microspheres, a transition metal salt and an elemental chalcogen, and pressing to obtain a tablet, the silica microspheres having a same or different particle diameters; and (2) sintering the tablet under hydrogen, and removing the silica microspheres to obtain the porous layered TMD. The porous layered TMD prepared by the method of the present invention has a high lattice edge exposure, which provides more active sites and higher catalytic activity, so the porous layered TMD can effectively catalyze the oxidation of alcohols to aldehydes or sulfides to sulfoxides under visible light irradiation.

The present disclosure provides regioselective methods for synthesizing intermediates useful in making prostacyclin. The methods include heating the compound of Formula 2 at a temperature of 180° C. to 185° C. Wherein the heating ##STR00001##
comprises irradiating the compound of formula 2 with microwave radiation.

The present disclosure provides regioselective methods for synthesizing intermediates useful in making prostacyclin. The methods include heating the compound of Formula 2 at a temperature of 180° C. to 185° C. Wherein the heating ##STR00001##
comprises irradiating the compound of formula 2 with microwave radiation.

The present invention is related to a process for preparing safinamide and salts thereof, preferably safinamide methanesulfonate, with high yields and high enantiomeric and chemical purity without the need of using highly pure intermediates. The process of the present invention is suitable for the production of safinamide and its salts, preferably safinamide methanesulfonate, at industrial scale.

The present invention is related to a process for preparing safinamide and salts thereof, preferably safinamide methanesulfonate, with high yields and high enantiomeric and chemical purity without the need of using highly pure intermediates. The process of the present invention is suitable for the production of safinamide and its salts, preferably safinamide methanesulfonate, at industrial scale.

The present invention is related to a process for preparing safinamide and salts thereof, preferably safinamide methanesulfonate, with high yields and high enantiomeric and chemical purity without the need of using highly pure intermediates. The process of the present invention is suitable for the production of safinamide and its salts, preferably safinamide methanesulfonate, at industrial scale.

The present invention relates to a novel p62 ligand compound, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for preventing or treating proteinopathies comprising the same as an active ingredient. The p62 ligand compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various proteinopathies by activating autophagy in cells and thus selectively eliminating in vivo proteins, organelles and aggregates.

The present invention relates to a novel p62 ligand compound, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for preventing or treating proteinopathies comprising the same as an active ingredient. The p62 ligand compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various proteinopathies by activating autophagy in cells and thus selectively eliminating in vivo proteins, organelles and aggregates.

The present invention refers to alkoxybenzaldehyde derivatives and precursors thereof. The invention further refers to perfume compositions and fragranced article comprising them.